New in vivo shuttle session: Syngeneic mouse tumor models for novel drug assessment and MoA deciphering
01 / 29 / 2020
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?
01 2020
Latest news
01 2020
New in vitro Shuttle Session: M2 Macrophage Suppression Assay
01 / 07 / 2020
Initiate the new year with our next in vitro shuttle session on our validated M2 macrophage suppression assay, which will take place by early February – thereby providing an opportunity to timely and cost-effectively assess novel immunotherapeutics.
01 2020
Featured model - Orthotopic glioblastoma mouse model
01 / 07 / 2020
Our syngeneic glioma mouse model, based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring, represents a suitable tool for chemo- and immunotherapy assessment. It closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration and tumor-induced immunosuppression.
Model responsiveness to standard Temozolomide and immune checkpoint inhibitors i.e. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies, makes it well-suited for testing candidate compounds for their efficacy, as single agents and/or in combination, in promoting anti-tumor activity.
12 2019
Explicyte poster at ESMO IO Congress 2019
12 / 17 / 2019
"Comprehensive assessment of anti-tumor PDL1 blockade effect in a sarcoma mouse model"
12 2019
Explicyte is proud to be a certified Nanostring partner - Let’s start the Digital Spatial Profiling revolution together
12 / 08 / 2019
To deal with this level of complexity, it’s therefore critical to benefit from technological platform allowing for specific investigation in compartments of interest (eg. tumor vs stroma). Thanks to the GeoMx® platform (Nanostring Inc.), which combines the spatial resolution of immunohistofluorescence with the high-plex gene/protein expression analysis, the Digital Spatial Profiling (DSP) revolution has started.
12 2019
Explicyte will be attending the ESMO Immuno-Oncology Congress In Geneva
12 / 03 / 2019
We will be attending the ESMO Immuno-Oncology Congress in Geneva, from December 11 to 14, 2019. We will be glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.
11 2019
Antibody-dependent cell-mediated cytotoxicity (ADCC) assay for in vitro testing
11 / 21 / 2019
See our case study below or download our white paper!
Many cells of the innate immunity work in concert with the adaptive immune system to effectively afford protection.
10 2019
Explicyte is CIR approved!
10 / 28 / 2019
We are proud to announce that the French Ministry for Higher Education and Research has recognised Explicyte / Immusmol SAS as a "Credit Import Recherche" (CIR) approved research and development service provider.
10 2019
Explicyte obtient l'agrément CIR !
10 / 24 / 2019
Nous sommes heureux de vous informer que le Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation a remis un avis favorable au dossier de demande d’agrément Crédit Impôt Recherche déposé par Explicyte / Immusmol SAS.
10 2019
In vivo syngeneic tumor models for novel drug assessment and MoA deciphering in a cost-saving way
10 / 09 / 2019
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?